<組織>技術室組織図

Demographical data (age; gender; hypertension, diabetes mellitus) type of occlusion, affected eye, SER, BCVA, AL, ONH parameters and SSI of affected and unaffected fellow eyes of our BRVO study subjects. (XLS 59 kb

<i>SDF1</i>-3’G(801)A allele and genotype frequencies in RVO patients with (n = 40) or without NV (n = 90) and p values of significance regarding the comparison between the two groups of RVO patients.

<p><i>SDF1</i>-3’G(801)A allele and genotype frequencies in RVO patients with (n = 40) or without NV (n = 90) and p values of significance regarding the comparison between the two groups of RVO patients.</p

Representative sample of the genotyping for <i>SDF1</i>-3’G(801)A by PCR-RFLP.

<p><i>Msp I</i> digestion of the PCR product of <i>SDF1</i> gene. DNA molecular weight marker is shown in <i>lane 1</i>. <i>Lane 2</i> represents sample at 302 bp denoting <i>SDF1</i>–3’homozygous (801)AA mutant genotype, <i>lane 3</i> shows bands at 302, 202 and 100 bp denoting heterozygous mutant <i>SDF1</i>-3’(801)GA and <i>lanes 4 and 5</i> at 202 and 100 bp denoting the wild type <i>SDF1</i>-3’(801)GG genotype.</p

Patients and controls characteristics.

<p>Patients and controls characteristics.</p

<i>SDF1-</i> 3’G(801)A allele and genotype frequencies in control and RVO group and p values of significance regarding the comparison between the RVO patients and the controls.

<p><i>SDF1-</i> 3’G(801)A allele and genotype frequencies in control and RVO group and p values of significance regarding the comparison between the RVO patients and the controls.</p